Intravitreal Combination of Triamcinolone Acetonide and Bevacizumab (Kenacort-Avastin) in Diffuse Diabetic Macular Edema

REFERENCES

• Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984;91:1–9.
   PubMed Web of Science ®Google Scholar
• Neelakshi Bhagat, Ruben A. Grigorian, Arthur Tutela, Marco A. Zarbin. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009:54:1–32.
   Google Scholar
• Mark W. Johnson. Etiology and treatment of macular edema. Am J Ophthalmol. 2009;147:11–21.
   Google Scholar
• Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796–806.
   PubMedGoogle Scholar
• Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long term visual results. Ophthalmology. 1991;98:1594–602.
   PubMed Web of Science ®Google Scholar
• Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920–7.
   PubMed Web of Science ®Google Scholar
• Maia JR, Takahashi BS,Costa RA, Scott IU, Takahashi WY. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. Am J Ophthalmol. 2009;147:291–7.
   PubMed Web of Science ®Google Scholar
• Diabetic retinopathy clinical research network ophthalmology a randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447–59.
   PubMed Web of Science ®Google Scholar
• Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006;26:999–1005.
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema. Ophthalmology. 2007;114:743–50.
   PubMed Web of Science ®Google Scholar
• Shimura M, Nakazawa T, Yasuda K.,Shiono T., et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol. 2008;145:854–61.
   PubMed Web of Science ®Google Scholar
• Cunningham ET Jr, Adamis AP, Altaweel M, et al. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747–57.
   Google Scholar
• Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690–6.
   PubMed Web of Science ®Google Scholar
• Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intracellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology. 2005;112:806–16.
   PubMed Web of Science ®Google Scholar
• Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol. 2008;53:139–49.
   PubMed Web of Science ®Google Scholar
• Jonas BJ, Spandau HU, Kamppeter AB, et al. Repeated intravitreal high dosage injections of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology. 2006;113:800–4.
   PubMed Web of Science ®Google Scholar
• Jemark CM, Dellacroce JT, Heffez J, Peyman GA. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol. 2007;52:503–22.
   Google Scholar
• Wirostko B, Wong YT, Simo’ R. Vascular endothelial growth factor and diabetic complications. Progr Retinal Eye Res. 2008;27:608–21.
   PubMed Web of Science ®Google Scholar
• Chylak LT Jr, Wolfe JK, Singer Dm, et al. The lens opacities classification system III. The longidutinal study of cataract study group. Arch Ophthalmol. 1993;111:831–6.
   Google Scholar
• Audren F, Lecleire-Collet A, Erginay A, et al. Intravitreal triamcinolone acetonide for diffuse macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol. 2006;142:794–9.
   PubMed Web of Science ®Google Scholar
• Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006;113:1706–12.
   PubMed Web of Science ®Google Scholar
• Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol. 2002;160:501–9.
   PubMed Web of Science ®Google Scholar
• Inatani M, Iwao K, Kawaji T, et al. Intraocular pressure elevation after injection of triamcinolone acetonide: a multicenter retrospective case-control study. Am J Ophthalmol. 2008;145:676–81.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113:1533– 8.
   PubMed Web of Science ®Google Scholar
• Audren F, Erginay A, Haouchine B, et al. Intravitreal triamcinolone acetonide for diffuse macular oedema: 6 month results of a prospective controlled trial. Acta Ophthalmol Scand. 2006;84:624–30.
   PubMedGoogle Scholar
• Marrshall J. The role of bevacizumab as first-line therapy for colon cancer. Semin Oncol. 2005;32:S43–7.
   Google Scholar
• Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age related macular degeneration. Ophthalmolgy. 2006;113:363–72.
   PubMed Web of Science ®Google Scholar
• Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2008;246:483–9.
   PubMed Web of Science ®Google Scholar
• Masoud S, Alireza R, Bijan B, et al. Intravitreal Bevacizumab (Avastin) alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Ophthalmic Comm Soc. 2007;27:1187–1195.
   Google Scholar
• Spandau UM, Derse M, Schmitz-Valckenberg P, et al. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular edema. Ophthalmology. 2005;89:999–1003.
   Google Scholar
• Roth DB,Verma V, Realini T, et al. Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology. 2009;116:455–60.
   Google Scholar